TY - JOUR
T1 - Correlation of tumour subtype with long-term outcome in small breast carcinomas
T2 - a Swedish population-based retrospective cohort study
AU - Rask, Gunilla
AU - Nazemroaya, Anoosheh
AU - Jansson, Malin
AU - Wadsten, Charlotta
AU - Nilsson, Greger
AU - Blomqvist, Carl
AU - Holmberg, Lars
AU - Wärnberg, Fredrik
AU - Sund, Malin
N1 - Funding Information:
Open access funding provided by Umeå University. This study was supported by grants from the Lions Cancer Research Foundation in Uppsala, Swedish Breast Cancer Association, the Percy Falk Foundation, VISARE NORR funding of the Northern County Councils Regional Federation (Grant Nos. VISARENORR750491 and VISARENORR931408) and ALF funding from Region Västerbotten.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/10
Y1 - 2022/10
N2 - Purpose: To investigate if molecular subtype is associated with outcome in stage 1 breast cancer (BC). Methods: Tissue samples from 445 women with node-negative BC ≤ 15 mm, treated in 1986–2004, were classified into surrogate molecular subtypes [Luminal A-like, Luminal B-like (HER2−), HER2-positive, and triple negative breast cancer (TNBC)]. Information on treatment, recurrences, and survival were gathered from medical records. Results: Tumour subtype was not associated with overall survival (OS). Luminal B-like (HER2−) and TNBC were associated with higher incidence of distant metastasis at 20 years (Hazard ratio (HR) 2.26; 95% CI 1.08–4.75 and HR 3.24; 95% CI 1.17–9.00, respectively). Luminal B-like (HER2−) and TNBC patients also had worse breast cancer-specific survival (BCSS), although not statistically significant (HR 1.53; 95% CI 0.70–3.33 and HR 1.89; 95% CI 0.60–5.93, respectively). HER2-positive BC was not associated with poor outcome despite no patient receiving HER2-targeted therapy, with most of these tumours being ER+. Conclusions: Stage 1 TNBC or Luminal B-like (HER2−) tumours behave more aggressively. Women with HER2+/ER+ tumours do not have an increased risk of distant metastasis or death, absent targeted treatment.
AB - Purpose: To investigate if molecular subtype is associated with outcome in stage 1 breast cancer (BC). Methods: Tissue samples from 445 women with node-negative BC ≤ 15 mm, treated in 1986–2004, were classified into surrogate molecular subtypes [Luminal A-like, Luminal B-like (HER2−), HER2-positive, and triple negative breast cancer (TNBC)]. Information on treatment, recurrences, and survival were gathered from medical records. Results: Tumour subtype was not associated with overall survival (OS). Luminal B-like (HER2−) and TNBC were associated with higher incidence of distant metastasis at 20 years (Hazard ratio (HR) 2.26; 95% CI 1.08–4.75 and HR 3.24; 95% CI 1.17–9.00, respectively). Luminal B-like (HER2−) and TNBC patients also had worse breast cancer-specific survival (BCSS), although not statistically significant (HR 1.53; 95% CI 0.70–3.33 and HR 1.89; 95% CI 0.60–5.93, respectively). HER2-positive BC was not associated with poor outcome despite no patient receiving HER2-targeted therapy, with most of these tumours being ER+. Conclusions: Stage 1 TNBC or Luminal B-like (HER2−) tumours behave more aggressively. Women with HER2+/ER+ tumours do not have an increased risk of distant metastasis or death, absent targeted treatment.
KW - Breast cancer
KW - Long-term outcome
KW - Molecular subtypes
KW - TMA
UR - http://www.scopus.com/inward/record.url?scp=85135605944&partnerID=8YFLogxK
U2 - 10.1007/s10549-022-06691-4
DO - 10.1007/s10549-022-06691-4
M3 - Article
C2 - 35933487
AN - SCOPUS:85135605944
SN - 0167-6806
VL - 195
SP - 367
EP - 377
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 3
ER -
